BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36966873)

  • 1. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation.
    Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Törlén J; Björklund A; Sohlberg E; Malmberg KJ
    Transplant Cell Ther; 2023 Jun; 29(6):376.e1-376.e11. PubMed ID: 36966873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections.
    Huenecke S; Cappel C; Esser R; Pfirrmann V; Salzmann-Manrique E; Betz S; Keitl E; Banisharif-Dehkordi J; Bakhtiar S; Königs C; Jarisch A; Soerensen J; Ullrich E; Klingebiel T; Bader P; Bremm M
    Front Immunol; 2017; 8():109. PubMed ID: 28239380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantity and Quality Reconstitution of NKG2A
    Hu LJ; Zhao XY; Yu XX; Lv M; Han TT; Han W; Huang XJ
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):1-11. PubMed ID: 30142416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
    Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
    Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
    Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
    Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Cytomegalovirus Reactivation and Expansion of CD56
    Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.
    Armand P; Kim HT; Sainvil MM; Lange PB; Giardino AA; Bachanova V; Devine SM; Waller EK; Jagirdar N; Herrera AF; Cutler C; Ho VT; Koreth J; Alyea EP; McAfee SL; Soiffer RJ; Chen YB; Antin JH
    Br J Haematol; 2016 Apr; 173(1):96-104. PubMed ID: 26729448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
    Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
    Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
    Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
    Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
    Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shaping of CD56
    Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2019; 10():547. PubMed ID: 30949182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings.
    Poirier N; Paquin V; Leclerc S; Lisi V; Marmolejo C; Affia H; Cordeiro P; Théorêt Y; Haddad E; Andelfinger G; Lavallée VP; Duval M; Herblot S
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.